Two-Thirds of Acute AAA Occur in Those Aged 75 Years and Older

This article originally appeared here.
Share this content:
Two-Thirds of Acute AAA Occur in Those Aged 75 Years and Older
Two-Thirds of Acute AAA Occur in Those Aged 75 Years and Older

THURSDAY, Aug. 20, 2015 (HealthDay News) -- Two-thirds of acute abdominal aortic aneurysm (AAA) events occur in those aged ≥75 years, with most events in men younger than 75 years occurring in smokers, according to a study published online Aug. 19 in the Journal of the American Heart Association.

Dominic P.J. Howard, D.Phil., from the University of Oxford in the United Kingdom, and colleagues conducted a prospective, population-based study to determine the incidence and outcome of acute AAA events, and the impact of screening.

The researchers identified 103 incident acute AAA events over the 12-year study period within the study population of 92,728. The incidence was 55, 112, and 298/100,000/year for men aged 65 to 74, 75 to 85, and 85 years or older, respectively. Sixty-six percent of all events occurred at age 75 years or older. Among those aged 65 to 74 years, incidence was highest among male smokers, with most (96.4 percent) events in men aged younger than 75 years occurring in ever-smokers. Using trial evidence of screening efficacy, extrapolating rates to the U.K. population, the current U.K. screening program would prevent 5.6 percent of aneurysm-related deaths. By 2030, 91 percent of deaths are expected to occur at age ≥75 years, with 28.6 percent occurring in women.

"Given that two-thirds of acute AAA occurred at ≥75 years of age, screening older age groups should be considered," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths